Clinical Trials and Research News Weekly Roundup | Ivermectin Moves Towards Mainstream

Sep 14, 2020 | Digital Media, Video, Weekly Roundup

TrialSite News Ivermectin
Ivermectin Moves Towards Mainstream: Recently, the National Institutes of Health (NIH) got around to formally addressing ivermectin in their COVID-19 Treatment Guidelines. Although their only recommendation is for use in clinical trials, that’s a start. TrialSite has been working tirelessly to chronicle and accumulate data centering on the off-label use, case series, observational and randomized clinical trial information possibly pointing to the future acceptance of this cheap and available drug as but one possible contributing way to help fight COVID-19. TrialSite has reported that in at least three randomized clinical trials (Egypt, Bangladesh, and Iraq), the use of the drug targeting early-stage COVID-19 patients leads to positive results; in addition to several observational and hospital approved case series efforts, TrialSite applauds the nation’s research institution for at least taking the time to acknowledge and review the recent Broward County study led by Dr. Jean Jacques Rajter. The apparent fact that this generic drug, which costs about $7 per pill in the US, may be useful as a treatment to alleviate symptoms of COVID-19 is given traction in the mainstream media in the United States as the Miami Herald recently embraced the topic showcasing the Broward County physician and his ICON study results. They also emphasized several doctors in Florida who are prescribing the drug, including Key West-based Dr. Bruce Boros, who reports that he is using the drug successfully to help COVID-19 patients in South Florida. https://www.trialsitenews.com/ivermec…
 
Patient’s Fiancé Tries to get Memorial Baptist Hospital to Treat her Future Husband with RLF-100 Leticia Pacheco’s fiancé is battling for his life against COVID-19. The family has heard that Aviptadil (RLF-100), not yet approved by the U.S. Food and Drug Administration (FDA), but purported to work, is currently an investigational drug used in clinical trials at the University of California, Irvine, the Miller School of Medicine, University of Miami, University of Louisville and Houston Methodist Hospital. Although still under investigation, the drug is available to those critically ill, and it also received Fast Track Designation from the FDA in July. https://www.trialsitenews.com/patient…
 
The Lancet: Russian “Sputnik V” Vaccine Safe and Produces Antibodies to COVID-19: On September 4, CNBC reported on a new Lancet study showing both “no serious adverse” effects and an antibody response from Russia’s vaccine. The trials involved 76 healthy volunteers; and the authors say that, “Large, long-term trials including a placebo comparison, and further monitoring are needed.” The chief of RDIF, Russia’s sovereign wealth fund, reported that the nation was “on track” to export vaccines by November. He notes that the UK and US are “following in Russia’s footsteps” as they consider approving Sputnik V. Early results showed no major side effects per the peer-reviewed article in The Lancet. “The two 42-day trials – including 38 healthy adults each – did not find any serious adverse effects among participants, and confirmed that the vaccine candidates elicit an antibody response,” the study noted. https://www.trialsitenews.com/the-lan…
 
 

0 Comments

Pin It on Pinterest